These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22069485)

  • 1. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia.
    Georgiadou D; Chroni A; Vezeridis A; Zannis VI; Stratikos E
    PLoS One; 2011; 6(11):e27037. PubMed ID: 22069485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and biophysical characterization of recombinant rat apolipoprotein E: similarities to human apolipoprotein E3.
    Tran TN; Kim SH; Gallo C; Amaya M; Kyees J; Narayanaswami V
    Arch Biochem Biophys; 2013 Jan; 529(1):18-25. PubMed ID: 23103361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
    Horie Y; Fazio S; Westerlund JR; Weisgraber KH; Rall SC
    J Biol Chem; 1992 Jan; 267(3):1962-8. PubMed ID: 1730728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
    Hoffmann MM; Scharnagl H; Panagiotou E; Banghard WT; Wieland H; März W
    J Am Soc Nephrol; 2001 Mar; 12(3):524-530. PubMed ID: 11181800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W; Hoffmann MM; Scharnagl H; Fisher E; Chen M; Nauck M; Feussner G; Wieland H
    J Lipid Res; 1998 Mar; 39(3):658-69. PubMed ID: 9548597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semisynthesis and segmental isotope labeling of the apoE3 N-terminal domain using expressed protein ligation.
    Hauser PS; Raussens V; Yamamoto T; Abdullahi GE; Weers PM; Sykes BD; Ryan RO
    J Lipid Res; 2009 Aug; 50(8):1548-55. PubMed ID: 19098282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy.
    Katsarou M; Stratikos E; Chroni A
    J Lipid Res; 2018 Dec; 59(12):2339-2348. PubMed ID: 30309894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Swapping the N- and C-terminal domains of human apolipoprotein E3 and AI reveals insights into their structure/activity relationship.
    Lek MT; Cruz S; Ibe NU; Beck WHJ; Bielicki JK; Weers PMM; Narayanaswami V
    PLoS One; 2017; 12(6):e0178346. PubMed ID: 28644829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-guided protein engineering modulates helix bundle exchangeable apolipoprotein properties.
    Kiss RS; Weers PM; Narayanaswami V; Cohen J; Kay CM; Ryan RO
    J Biol Chem; 2003 Jun; 278(24):21952-9. PubMed ID: 12684504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy.
    Georgiadou D; Stamatakis K; Efthimiadou EK; Kordas G; Gantz D; Chroni A; Stratikos E
    J Lipid Res; 2013 Jan; 54(1):164-76. PubMed ID: 23110818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.
    Matsunaga A; Saito T
    Clin Exp Nephrol; 2014 Apr; 18(2):220-4. PubMed ID: 24570178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural variation in human apolipoprotein E3 and E4: secondary structure, tertiary structure, and size distribution.
    Chou CY; Lin YL; Huang YC; Sheu SY; Lin TH; Tsay HJ; Chang GG; Shiao MS
    Biophys J; 2005 Jan; 88(1):455-66. PubMed ID: 15475580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
    Wardell MR; Rall SC; Brennan SO; Nye ER; George PM; Janus ED; Weisgraber KH
    J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity.
    Dong LM; Innerarity TL; Arnold KS; Newhouse YM; Weisgraber KH
    J Lipid Res; 1998 Jun; 39(6):1173-80. PubMed ID: 9643348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia.
    Mann WA; Meyer N; Weber W; Meyer S; Greten H; Beisiegel U
    J Lipid Res; 1995 Mar; 36(3):517-25. PubMed ID: 7775863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement of helix 1' enhances the lipid binding activity of apoE3 N-terminal domain.
    Redmond KA; Murphy C; Narayanaswami V; Kiss RS; Hauser P; Guigard E; Kay CM; Ryan RO
    FEBS J; 2006 Feb; 273(3):558-67. PubMed ID: 16420479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of
    Bea AM; Larrea-Sebal A; Marco-Benedi V; Uribe KB; Galicia-Garcia U; Lamiquiz-Moneo I; Laclaustra M; Moreno-Franco B; Fernandez-Corredoira P; Olmos S; Civeira F; Martin C; Cenarro A
    Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):1066-1077. PubMed ID: 37051929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A monomeric, biologically active, full-length human apolipoprotein E.
    Zhang Y; Vasudevan S; Sojitrawala R; Zhao W; Cui C; Xu C; Fan D; Newhouse Y; Balestra R; Jerome WG; Weisgraber K; Li Q; Wang J
    Biochemistry; 2007 Sep; 46(37):10722-32. PubMed ID: 17715945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS; Fazio S; Mahley RW
    J Biol Chem; 1994 May; 269(18):13421-8. PubMed ID: 8175773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural characterization of a low density lipoprotein receptor-active apolipoprotein E peptide, ApoE3-(126-183).
    Raussens V; Mah MK; Kay CM; Sykes BD; Ryan RO
    J Biol Chem; 2000 Dec; 275(49):38329-36. PubMed ID: 10986285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.